Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns
Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really does repeat.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Retirees rarely need reminding that a great income stock is built during a recession, not during a bull market. The trio below has done exactly that, funding higher payouts through every downturn since the 1960s. Procter & Gamble (NYSE:PG | PG Price Prediction) put a fine point on it in its most recent 10-K, declaring the latest quarterly rate its 70th consecutive year of dividend increases and 136th consecutive year of dividend payments. Add Johnson & Johnson (NYSE:JNJ) and Coca-Cola (NYSE:KO) and you have three Dividend Kings whose commitments were forged through the stagflation of the 1970s, the double-dip recession of the early 1980s, the 1990 downturn, the dot-com bust, the 2008 financial crisis, and the 2020 pandemic shock.
Procter & Gamble: 70 Straight Years of Raises
P&G is the household-and-personal-care giant behind Tide, Pampers, Gillette, Crest, and Olay, organized into five reportable segments across Beauty, Grooming, Health Care, Fabric & Home Care and Baby, Feminine & Family Care. The current quarterly dividend is $1.0885 per share, with an annualized forward rate of $4.354. The trailing yield sits at 2.98%, and shares recently traded at $146.23.
Dividend safety here is a study in slow-moving conviction. In FY2026 P&G generated $19.56 billion in operating cash flow and $15.84 billion in free cash flow, up 12.74% year over year, on $87.03 billion in revenue and $16.14 billion in net income. Management has already telegraphed FY2027 plans of roughly $10 billion in dividends and $5 billion in buybacks, comfortably inside prior-year cash generation. The balance sheet carries $9.94 billion in cash against $54.31 billion in shareholders’ equity. The track record, verified in the company’s own filing, is 70 consecutive years of dividend increases and 136 consecutive years of dividend payments dating to incorporation in 1890.
Bull case: P&G collects predictable cash from repeat purchases of consumable staples, then routes it back via one of the most institutionalized dividend policies in the S&P 500. A beta of 0.377 and a trailing P/E of 22 support a defensive allocation.
Risk: Management has flagged a roughly $1 billion after-tax headwind from higher commodity, energy, and transportation costs, plus tariff uncertainty and softer volume/pricing in Family Care. That is the sort of margin pressure that can slow the pace of future raises even when the streak continues.
Johnson & Johnson: 64 Straight Years of Raises
Johnson & Johnson is the diversified healthcare franchise built on Innovative Medicine (Darzalex, Tremfya, Carvykti, Stelara) and MedTech (cardiovascular, surgery, vision, orthopaedics). In April 2026 the board lifted the quarterly payout 3.1% to $1.34 per share, marked in the filing as the 64th consecutive year of dividend increases. That reaches back to the early 1960s and covers every US recession since. The current yield is 1.98%, with shares at $271.22 after a 30.8% year-to-date advance.
The safety read is exceptional. FY2025 delivered $94.19 billion in revenue, $26.80 billion in net income and $19.7 billion in free cash flow, which sits well above the annualized dividend commitment of $5.36 per share across roughly 2.41 billion shares outstanding. Diluted EPS TTM of $8.62 against the annualized rate implies clean payout coverage. Management’s FY2026 outlook calls for revenue of $100.3 billion to $101.3 billion and adjusted EPS of $11.45 to $11.65. J&J is also one of only a handful of US corporates historically holding a AAA credit rating, and Q1 growth engines included Darzalex +22.5% to $3.96 billion and Tremfya +68.3% to $1.61 billion.
Bull case: An oncology and immunology pipeline funding a fortress dividend, with MedTech cash flow providing ballast. A trailing P/E of 31 looks less demanding against a forward P/E of 21.
Risk: Stelara biosimilar erosion, cited at -59.7% year over year in Q1, plus ongoing talc-related litigation charges of $330 million in Q1 and execution risk on the planned Orthopaedics separation. Growth from Darzalex, Tremfya, and Carvykti has to keep offsetting patent-cliff drag.
Coca-Cola: A Dividend King Since the Kennedy Era
Coca-Cola concentrates and syrups reach virtually every country on earth, with the branded lineup spanning Trademark Coca-Cola, Coke Zero Sugar, fairlife, Costa, Powerade and Minute Maid. The current quarterly dividend is 53 cents per share, an annualized forward rate of $2.12. The yield is 2.41%, with shares at $87.81. Coca-Cola’s dividend record is widely recognized as one of the longest in the market. The dividend dataset available at generation documents uninterrupted quarterly payments and a rising annual rate from 16 cents per share in 1999 to 53 cents in 2026, spanning the dot-com recession, the 2008 crisis, and 2020. The pre-1999 streak into the Kennedy-era 1960s is corporate history the dataset does not itself confirm, so treat the exact consecutive-year count as widely reported rather than newly verified here.
Dividend safety is anchored by staples-grade margins. Coca-Cola posted a gross margin of 61.63%, operating margin of 28.71%, and net margin of 27.34%, with return on equity of 45.97%. FY2026 guidance calls for organic revenue growth around 5%, comparable EPS growth of 9% to 10%, and free cash flow of roughly $12.4 billion, against a dividend commitment of about $2.12 per share on 4.30 billion shares outstanding. Interest coverage is 8.32x, and net debt to EBITDA sits at 2.49x. Q2 delivered $13.38 billion in revenue, up 6.7% year over year, with global volume growth of 5% and Coca-Cola Zero Sugar up 16%.
Bull case: Pricing power on a truly global scale, an asset-light bottler system that converts scale into free cash, and a dividend policy the board treats as sacrosanct. A trailing P/E of 27 is not cheap, but the earnings stream is unusually predictable.
Risk: Ongoing US IRS tax litigation, six fewer selling days in Q4 2026 versus Q4 2025, consumer-affordability pressure in Asia Pacific, and the lingering fairlife cybersecurity incident. Coca-Cola stock has already rallied 36.65% over the past year, so entry-yield today is skinnier than long-term averages.
Counterpoint for Income Portfolios
A streak this long creates its own institutional pressure. Boards that have raised every year since the Kennedy administration will occasionally protect the dividend at the expense of reinvestment, buybacks, or optionality on tuck-in M&A. A record is evidence of commitment, never a guarantee, and each of these three has meaningful near-term crosscurrents: P&G’s ~$1 billion commodity and tariff headwind, J&J’s Stelara cliff and litigation overhang and Coca-Cola’s tax dispute and softer Asia consumer.
What ties the trio together is the coverage math. Free cash flow of $15.84 billion at P&G, $19.70 billion at J&J, and guided $12.4 billion at Coca-Cola fund payouts many times over. For income portfolios built to survive the next recession the way these dividends survived the last seven, this is the shortlist (we ranked 10 Dividend Kings by valuation right now in a free report you can grab here).
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
